Pemvidutide
ALT-801 · GLP-1/glucagon dual agonist
Altimmune GLP-1/glucagon dual agonist (ALT-801). Phase 2 MOMENTUM. Not a US obesity pen. This site will not treat MASH from a peptide page.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight7/10
Phase 2 MOMENTUM. Ceiling 8 for Phase 2–3; haircut to 7 because Phase 2 is not a label and muscle-sparing language is a trial observation, not a guarantee on a cake.
Compound card
- Sequence
- GLP-1/glucagon dual agonist (ALT-801)
- Class
- Once-weekly dual agonist (Altimmune; not FDA-approved as of this review)
- Formula
- Dual GLP-1/GCGr peptide analog
- Status
- Not FDA-approved · research use
How it works
Pemvidutide (ALT-801) is a balanced GLP-1/glucagon dual receptor agonist developed by Altimmune. Its differentiating design: balanced 1:1 GLP-1:GCGr activity ratio, which maximises energy expenditure (via glucagon) while maintaining appetite suppression (via GLP-1). Phase 2 MOMENTUM trial showed 15.6% body weight reduction at 2.4 mg over 48 weeks - with notably superior muscle mass preservation vs semaglutide alone (lean mass loss was 22% lower). This muscle-sparing profile makes it particularly relevant for body composition optimization.
Source: PMID: 37578887 (MOMENTUM Phase 2)
Research Use Cases
- ✓Obesity with Muscle Preservation Priority: High
- ✓Metabolic Liver Disease (MASH): Emerging
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Phase 2 Protocol | 1.2 mg / 1.8 mg / 2.4 mg | Once weekly (SC) | Escalating dose over 12 weeks then maintenance. Phase 3 ongoing. |
Administration
Timeline
Who it is for
Obesity with Muscle Preservation Priority
HighKey differentiator: 22% lower lean mass loss vs semaglutide. Ideal for body composition goals.
Metabolic Liver Disease (MASH)
EmergingStrong hepatic fat reduction signal via glucagon receptor activation.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 2.4 mg research/compounded cake | 1.0 mL BAC | 2.4 mg/mL | 1.2 mg = 0.50 mL = 50 units on a U-100. This is not trial supply. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
Investigational - not FDA-approved. Phase 3 ongoing. GI profile consistent with GLP-1 class. Muscle preservation advantage may be clinically meaningful for active patients and older adults.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- MOMENTUM lean-mass language is a Phase 2 observation, not a body-recomp indication.
- This site will not treat MASH or NAFLD from a peptide page.
- Not interchangeable with survodutide or mazdutide. Different sponsors, different ratios.
Verdict
Pemvidutide is Altimmune’s dual GLP-1/glucagon program, often discussed for liver fat. Phase 2 is not a US obesity pen. A research vial is not MOMENTUM.
Interactions & Contraindications
Investigational - not FDA-approved. Phase 3 ongoing. GI profile consistent with GLP-1 class. Muscle preservation advantage may be clinically meaningful for active patients and older adults.
Frequently Asked Questions
Why does pemvidutide preserve muscle better than semaglutide?▼
Is pemvidutide FDA-approved?▼
References
- Altimmune Inc. (MOMENTUM Phase 2 data) “"Pemvidutide (ALT-801) Phase 2 MOMENTUM trial results".” Obesity Week / Press Release (2024).
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code